10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

PABPC3 Antibody (N-Term)

Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP22175a

Product Information

Application	WB, FC, IHC-P, E
Primary Accession	Q9H361
Reactivity	Human
Predicted	Mouse, Rat, Bovine, Canine, Rabbit, Chicken
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit IgG
Clone Names	RB55063
Calculated MW	70031

Additional Information

Gene ID	5042
Other Names	Polyadenylate-binding protein 3, PABP-3, Poly(A)-binding protein 3, Testis-specific poly(A)-binding protein, PABPC3, PABP3, PABPL3
Target/Specificity	This PABPC3 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 84-117 amino acids from human PABPC3.
Dilution	WB~~1:2000 FC~~1:25 IHC-P~~1:100~500 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	PABPC3 Antibody (N-Term) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	PABPC3
Synonyms	PABP3, PABPL3
Function	Binds the poly(A) tail of mRNA. May be involved in cytoplasmic regulatory

processes of mRNA metabolism. Binds poly(A) with a slightly lower affinity as compared to PABPC1.

Cellular Location Cytoplasm.

Tissue Location Testis specific..


Background

Binds the poly(A) tail of mRNA. May be involved in cytoplasmic regulatory processes of mRNA metabolism. Binds poly(A) with a slightly lower affinity as compared to PABPC1.


References

Feral C.,et al.Nucleic Acids Res. 29:1872-1883(2001).
Wiemann S.,et al.Genome Res. 11:422-435(2001).


Images



AP22175a staining PABPC3 in human colon tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hours at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.




AP22175a staining PABPC3 in human testis tissue sections by Immunohistochemistry (IHC-P - paraformaldehyde-fixed, paraffin-embedded sections). Tissue was fixed with formaldehyde and blocked with 3% BSA for 0. 5 hour at room temperature; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hours at 37°C. A undiluted biotinylated goat polyvalent antibody was used as the secondary antibody.



Overlay histogram showing HepG2 cells stained with AP22175a(green line). The cells were fixed with 2% paraformaldehyde (10 min) and then permeabilized with 90% methanol for 10 min. The cells were then icubated in 2% bovine serum albumin to block non-specific protein-protein interactions followed by the antibody (AP22175a, 1:25 dilution) for 60 min at 37ºC. The secondary antibody used was Goat-Anti-Rabbit IgG, DyLight® 488 Conjugated Highly Cross-Adsorbed(OH191631) at 1/200 dilution for 40 min at 37ºC. Isotype control antibody (blue line) was rabbit

IgG1 (1µg/1x10^6 cells) used under the same conditions. Acquisition of >10, 000 events was performed.



All lanes : Anti-PABPC3 Antibody (N-Term) at 1:2000 dilution Lane 1: Daudi whole cell lysate Lane 2: HepG2 whole cell lysate Lane 3: Jurkat whole cell lysate Lane 4: K562 whole cell lysate Lane 5: MOLT-4 whole cell lysate Lane 5: Raji whole cell lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size : 70 kDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.